On behalf of the partnership, the $21 million is not just from the common drug review, but a result of all the things we've been doing around pharmacy. We're doing some things like joint negotiations. So if we go into a province like British Columbia, the six partners, or many of us, will work together to try to have a similar negotiating agreement in that particular province so we will get the same prices.
So the common drug review would only be a part of it. The larger part would be from things like our negotiation strategies—and again, trying to get the best dollar for the drugs we do have listed.